• Turn Therapeutics highlighted lead topical candidate GX-03, a non-systemic IL-36/IL-31 inhibitor program for moderate-to-severe atopic dermatitis, with a Phase 2 randomized controlled trial underway and topline data expected mid-2026.
• Phase 2 design calls for about 120 patients, with an adaptive option to expand to 200; primary endpoint is change in IGA score versus vehicle at week 8.
• Presentation cited more than 200,000 patients previously receiving GX-03 in other cleared uses, with zero reported adverse events, including a 53-patient RIPT study that reported no adverse reactions across more than 580 applications.
• Management outlined a development path targeting Phase 3 initiation in 2027, with a planned GX-03 launch in 2029, subject to trial outcomes and capital availability.
• Turn also positioned PermaFusion, an emulsifier-free, oil-based delivery platform, as a proprietary approach to improve topical penetration across skin, nails, and mucous membranes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.